Special Issue

Ferroptosis Pathways in Neurodegenerative and Neuropsychiatric Diseases

Message from the Guest Editor

Ferroptosis is a newly discovered pathway towards programmed cell death. It is caused by an excess of free intracellular iron that leads to cytotoxic lipid (hydro-) peroxidation. Erythroid 2-related factor 2 (Nrf2) is an emerging regulator of cellular resistance to oxidants, including those generated by iron-associated radicals. A growing body of evidence suggests that perturbations of iron homeostasis play a key role in the occurrence and development of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and vascular dementia, which suggests that ferroptosis may be involved in regulating the progression of not only neurodegenerative but also neuropsychiatric diseases. The Special Issue welcomes reviews, as well as original in vivo, in vitro, and preclinical research focused on the regulatory mechanism of ferroptosis and its various effects in neurodegenerative diseases, in order to provide a reference for the research on ferroptosis in neurodegenerative and neuropsychiatric diseases.

Guest Editor

Dr. Jack T. Rogers

Neurochemistry Laboratory, Department of Psychiatry-Neuroscience, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, Charlestown, Boston, MA 02129, USA

Deadline for manuscript submissions

closed (15 August 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/177748

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).